Since its establishment in March 2020, Shanghai Vitalgen BioPharma Co., Ltd. (Vitalgen) has been dedicated to translating cutting-edge gene delivery and gene editing techniques into clinically effective treatments for patients with unmet medical needs.

Vitalgen boasts a team of leading academic researchers and experienced R&D executives who possess extensive expertise in drug discovery, spanning from scientific concepts to marketed products. By leveraging our proprietary ViCas® novel CRISPR/Cas editing tools, ViLNP® lipid nanoparticles, and ViVec® AAV capsids, we have established a commercial production platform that adheres to GMP standards. We are committed to developing innovative gene therapies aimed at treating hereditary diseases and neurodegenerative disorders for both local and global markets. Several of our products have already entered the clinical research phase.